




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/34, 31/35, 31/415, 31/44, 31/445, 31/505, 31/47, C07C 275/26, 275/28, C07D 211/08, 213/56, 213/58, 215/12, 233/61, 235/14, 239/32, 265/30, 307/22, 309/14</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/07420</p> <p>(43) International Publication Date: 26 February 1998 (26.02.98)</p>
<p>(21) International Application Number: PCT/US97/14854</p> <p>(22) International Filing Date: 22 August 1997 (22.08.97)</p> <p>(30) Priority Data: 60/025,791 23 August 1996 (23.08.96) US</p> <p>(71) Applicant (for all designated States except US): AGOURON ACQUISITION CORP. [US/US]; 10350 North Torrey Pines Road, La Jolla, CA 92037-1022 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): GREGOR, Vlad, Edward [US/US]; 2711 Caminito Verdugo, Del Mar, CA 92014 (US). HONG, Yufeng [CN/US]; 11980 Ashley Place, San Diego, CA 92128 (US). LING, Anthony, Lai [US/US]; 10933 Caminito Cuesta, San Diego, CA 92131 (US). TOMPKINS, Eileen, Valenzuela [US/US]; 3145 Cowley Way #133, San Diego, CA 92117 (US).</p> <p>(74) Agent: ALTMAN, Daniel, E.; Knobbe, Martens, Olson & Bear, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>

(54) Title: NEUROPEPTIDE-Y LIGANDS

(57) Abstract

There are disclosed novel neuropeptide Y ligands having general formula (I) wherein the symbols W, A, D, R¹, R², R³, R⁴ are further defined in the description. Compounds of formula (I) are agonists and antagonists of neuropeptide Y, and are therefore useful as regulators of neuropeptide Y activity and in treating disorders related thereto.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

NEUROPEPTIDE-Y LIGANDS

The invention relates to compounds that modulate the activity of neuroendocrine hormones. It relates particularly to neuroendocrine receptor ligands and methods for their use.

BACKGROUND OF THE INVENTION

5 Cells of the neuroendocrine system secrete neuropeptide hormones that modulate a diverse array of physiological activities. In addition to neurotransmission, neuropeptides regulate secretory functions of adenohypophyseal and pancreatic cells as well as cells of the adrenal cortex and the digestive system. The hormone termed neuropeptide Y is co-released with norepinephrine from postganglionic neurons and participates along with that hormone in regulating vascular
10 smooth muscle tone and maintaining blood pressure. Agonists and antagonists of neuropeptide-Y are therefore useful in treating clinical disorders relating to both hypotension and hypertension.


 Receptor binding ligands are typically polypeptides, for example, neuropeptide-Y, a 36 amino acid polypeptide sequence whose composition is known. Receptor activity can be inhibited by competitive binding of an antagonist of the neuropeptide to the Y-receptor. Several synthetic
15 antagonist species of neuropeptide-Y have been developed. Among these are corresponding amino acid sequences wherein some of the native L-amino acids are replaced by corresponding D-amino acids (U.S. Patent No. 5,328,899).

 Neurons bind neuropeptide-Y through several distinct Y-receptors; receptors Y1, Y2, Y3, Y4, Y5 are known. The neuroendocrine Y1 receptor is one of those believed to be particularly
20 associated with appetite, and synthetic neuropeptide ligands that selectively bind to the Y1 receptor and have antagonistic activity to neuropeptide-Y are believed to be anorectic agents useful in treating obesity.

 Other non-peptide neuropeptide-Y antagonist species have been developed for pharmacologic use. Among these are benzylamine derivatives of molecular systems comprising
25 phenyl, thienyl, pyridyl or pyrimidine groups (Peterson, JM et al. WO9614307); sulfanilyl derivatives of quinoline (Downing, DM et al. 211th Amer. Chem. Soc. Meeting, March 1996); phenylsulfonyl derivatives of aniline-based compounds (Wright, JL et al., 211 Amer. Chem. Soc. Meeting, March, 1996); raloxiphen, and a benzothiophene derivative of pyrrolidine or piperidino groups having antiestrogen properties (U.S. Patent No. 5,504,094 to Bruns et al.). Also described are sulfamyl
30 derivatives of phenylalanine-amidine-containing compounds (U.S. Patent 5,506,258 to Christophe et al.); and bicyclic neuropeptide-Y receptor antagonists comprising substituted benzofurans, benzothiophenes, or indoles (WO96/12489 to Eli Lilly).

DESCRIPTION OF THE INVENTION

Groups of derivatized compounds having a general core amidino-urea or diamidino-urea structure have been found to be highly potent interactive compounds which bind to the neuropeptide-Y receptor and may stimulate, not stimulate or partially stimulate a response pathway associated with that receptor thus acting as agonists, partial agonists, antagonists or mixed agonist-antagonists of neuropeptide-Y. These compounds have the general formula I



wherein


A is O, S or N-R, wherein R is lower alkyl ($\text{C}_1\text{-C}_8$);

D is O, S or N-R⁷;

W is N, CH or C-R⁸;

R¹ and R³ are independently H, straight or branched, cyclic or acyclic, saturated or unsaturated $\text{C}_1\text{-C}_{14}$ alkyl radicals, optionally substituted by hydroxy, lower alkoxy, alkylthio, aryloxy or arylthio groups, wherein said aryl-bearing groups are optionally substituted by halogen, lower alkoxy, alkylthio, lower alkyl, trifluoromethoxy, trifluoroethoxy or trifluoromethyl groups, and optionally said alkyl groups are substituted by cyclic structures selected from the group consisting of rings having a ring size of from 3 to 10 atoms, such as cyclohexyl or cyclopentyl, or said alkyl groups are substituted by aromatic or heteroaromatic moieties, said aryl or heteroaryl groups optionally containing substituents on the aryl ring selected from the group consisting of lower alkyl, alkoxy, amino, lower alkylamino, lower acylamino, halogens, and trifluoromethyl or trifluoromethoxy groups;

R² is



Wherein

W₂ is C=O, SO₂, C(O)NH; SO; or is absent;

Q is


(a) a substituted or unsubstituted $(\text{-CH}_2\text{-})_z$, wherein $z = 1$ to 12 , and when $\text{-CH}_2\text{-}$ is substituted, the substituting groups are lower alkyl, aryl or heteroaryl; and when $z > 1$, at least one $\text{-CH}_2\text{-}$ group is optionally replaced by a heteroatom selected from the group consisting of O, S, or a substituted or unsubstituted N, wherein the substituting

3

moiety is selected from the group consisting of lower alkyl, aryl, heteroarylalkyl and hydrogen;

5

(b) a saturated carbocyclic or heterocyclic ring of the formula $(-CH_2-)_x$




10

wherein l and m are 0-5, and wherein $x = 3-12$, preferably 3-8, and optionally, one or more $-CH_2-$ groups are substituted by a radical selected from the group consisting of saturated or unsaturated lower alkyl, cycloalkyl, aryl and heteroaryl; and optionally at least one of the $-CH_2-$ groups is replaced by a heteroatom selected from the group consisting of O, S, Se and substituted or unsubstituted N, and when N is substituted, the substituting group is selected from the group consisting of lower alkyl, aryl, heteroaryl and hydrogen;

15

(c) a carbocyclic or heterocyclic aromatic ring of the formula $(-CH=CH-)_y$:



20


wherein l and m are 0-5, and wherein $y \geq 2$ and optionally at least one of the $-CH-$ groups is substituted by X^1 , X^2 or both X^1 and X^2 wherein X is any ring substituent, for example saturated or unsaturated, linear or branched alkyl groups, lower alkoxy groups or halogens, and optionally, at least one of the $-CH-$ groups is replaced by N, or alternatively, one of the $-CH=CH-$ groups is replaced by a heteroatom selected from the group consisting of O, S, Se and $N-R^{11}$; also optionally, at least one of the $-CH=CH-$ groups is a junction to which another ring structure, either saturated or unsaturated can be fused, thus forming condensed aromatic or heteroaromatic systems selected, for example, from the group consisting of naphthalene, indole, benzofuran, quinoline, quinazoline and benzodioxane classes;

25


X^3 is a substituent on Q which can be H, lower alkyl, aryl, lower alkoxy, hydroxy, trifluoromethyl, and similar common ring substituents.

30

R^4 is selected from the group consisting of the following general formulas:



1(a)



1(b)

35

wherein A^1 is O, S, NH or N-lower alkyl or aryl;

R^5 to R^9 , R^{11} and R^{12} are independently selected from the group consisting of H, linear or branched, saturated or unsaturated, cyclic or acyclic, substituted or unsubstituted C_1 to C_{14} alkyl radicals, or aryl or heteroaryl radicals, and when any one of R^5 to R^9 , R^{11} or R^{12} is a substituted aryl or heteroaryl radical, the substituting group is selected from members of the group consisting of halogen, lower alkoxy, alkylthio, lower alkyl, trifluoromethoxy and trifluoromethyl, and when any one of R^5 to R^9 , R^{11} or R^{12} is a substituted alkyl radical, the substituting moiety is selected from the group consisting of non-aromatic cyclic systems having from 3 to 14 ring atoms, and aromatic and heteroaromatic systems and heterocyclic rings having from 4-12 ring members, and said aromatic and heteroaromatic rings optionally are substituted by radicals selected from the group consisting of lower alkyl, alkoxy, amino, lower alkylamino, lower acylamido, halogens, perfluoroalkyl, and perfluoro-lower alkoxy; or

R^6 is H, C_1 to C_{14} alkyl, straight or branched, cyclic or acyclic, saturated or unsaturated; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; condensed aryl-lower alkyl; condensed heteroaryl-lower alkyl; diaryl-lower alkyl; bis-heteroaryl-lower alkyl; or heteroaryl-lower alkyl-aryl; or partially or fully saturated derivatives thereof; or R^6 can be $R^{6'}$ which is R^6 -NH or R^6 -N-lower alkyl;

R^{10} is hydrogen, C_1 - C_{12} alkyl, straight or branched, saturated or unsaturated, cyclic or acyclic groups, optionally containing double or triple bonds; aryl, optionally substituted with groups such as halogen, lower alkyl, alkoxy, aminoalkyl, di-(lower alkyl)-amino-lower alkyl, hydroxy; arylalkyl; aryloxyalkyl; 2-tetrahydrofurfuryl; 3-tetrahydrofurfuryl; terminal hydroxyalkyl with C_2 - C_{10} hydrocarbon chains and amidoalkyl such as 2-acetamidoethyl; or

R^9 and R^{10} can optionally form a 3 to 10-membered ring, preferably 4 to 8-membered, for example, piperidine, pyrrolidine, morpholine, piperazine, 4-methyl piperazine or tetrahydroisoquinoline.


The compounds of the present invention may have one or more asymmetric centers and it is intended that stereoisomers, as separated, pure, or partially separated stereoisomers or racemic mixtures thereof are included within the scope of the invention. Lower alkyl is defined to mean having from 1 to 8 carbon atoms.

The compounds of this invention are generally utilized as the free base or as a pharmaceutically acceptable derivative thereof. One example is an acid addition salt having the utility of the free base. Such salts are prepared in a conventional manner by treating a solution or suspension of the free base of formula I with one or more chemical equivalents of a


5

pharmaceutically acceptable acid, for example, organic and inorganic acids, for example: maleic, fumaric, benzoic, ascorbic, pantoic, succinic, bismethylene salicylic, methanesulfonic, ethanedithionyl, acetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, hydrochloric, hydrobromic, sulfuric, phosphoric or nitric acids. Physiologically acceptable salts of a compound with an hydroxy group include the anion of said compound in combination with a suitable cation such as sodium or ammonium ion. "Physiologically acceptable" means non-injurious to the subject.

The compounds of the invention are of two general types containing either an amidino-urea group or diamidino-urea group as a core structure:





Core Structure (a)



Core Structure (b)

said groups being derivatized with various aliphatic and aromatic moieties.

Core structure (a) comprises an amidino-substituted urea moiety and core structure (b) comprises a bis-amidino-substituted urea moiety. In each core structure, any of the imino N can optionally be further substituted as shown below by substitution according to the general formula I:



wherein R^1 , R^3 , R^5 , R^7 , R^9 , R^{10} , X^3 , and A^1 are as defined above.

6

Preferred compounds have the structures




Figure 1a




Figure 1b

7





Figure 1c



5

Figure 1d

8








Figure 1e

5 Particularly preferred compounds have the structures





10





- 5 Wherein Y' and Y'' are independent and can be H, lower alkyl, O-lower alkyl, halogen, CN, NO₂, OH, or other common aromatic ring substitutions.




Representative compounds of the present invention also include the following:







10





15





5







10







11



5




10









15



12



.5





10









15

13





5







10



14





5







10



15







15







5

10






15

16





5







10



17







5







10



18



5



10

Depending on the varied structural features incorporated therein, the compounds of the invention either act peripherally without significant penetration of the blood-brain barrier to beneficially affect various physiological processes, or act centrally to beneficially affect various aspects of mammalian, including human, neurological disorders and behavior.

15

These compounds are specifically designed and are herein disclosed as pharmacological agents, useful for, but not limited to, the treatment of the following conditions: septic shock, anxiety

(anxiolytics), infertility, hypertension, congestive heart failure, obesity, type II diabetes, genitourinary dysfunction and other pathological conditions. These compounds are accordingly intended for specific use as feeding stimulants, fertility stimulants, bronchodilators, vasodilating agents to beneficially affect the reperfusion of ischemic organs and also as feeding suppressants, depending on the manner in which the particular compound interacts with the neuropeptide-Y receptor. The compounds of the invention, their stereoisomers, enantiomers, or mixtures and the use thereof in pharmaceutical formulations for the treatment of disease is within the scope of the invention. A marked difference in potency has been observed among enantiomers of the same compounds, and advantageous use of these structurally based differences is contemplated.

The compounds according to the invention, which may also be referred to as active ingredients, may be administered for therapy by any suitable route including oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous and intradermal). It will be appreciated that the preferred route will vary with the condition and age of the recipient, the nature of the condition to be treated, and the chosen active ingredient.

In general, a dose will be in the range of 0.01 to 200 mg per kilogram body weight of the recipient per day, more particularly, in the range of 0.1 to 120 mg/kg, preferably 1 to 90 mg/kg and most preferably 10 mg/kg/day. The desired dose is preferably presented as two, three or more subdoses administered in unit dosage forms, for example, containing 5 to 1500 mg, preferably 10 to 250 mg and most preferably 100 mg of active ingredient in unit dosage form.

For parenteral routes, such as intravenous, intrathecal, intramuscular and similar administration, typically doses are on the order of from about 1/2 to about one order of magnitude lower than the dose employed for oral administration.

The compounds may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses. Pharmaceutical preparations containing the compounds of the invention in combination with various carriers are produced by conventional dissolving and lyophilizing processes to contain from approximately 0.1% to 100%, preferably from approximately 1% to 50% of the active ingredient. They can be prepared as ointments, salves, tablets, capsules, powders or sprays, together with effective excipients, vehicles, diluents, fragrances or flavor to make palatable or pleasing to use.

For parenteral administration, solutions of the novel compounds of formula I in sterile aqueous solution, aqueous propylene glycol or sesame or peanut oil may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for

intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. The pharmaceutical compositions formed by combining the novel compounds of formula I and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient in the form of powder or granules, as a solution or suspension in an aqueous or nonaqueous liquid, or as an oil-in-water or water in oil liquid emulsion.

Tablets or other non-liquid oral compositions may contain acceptable excipients, known to the art for the manufacture of pharmaceutical compositions, comprising diluents, such as lactose or calcium carbonate; binding agents such as gelatin or starch; and one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring or preserving agents to provide a palatable preparation. Moreover, such oral preparations may be coated by known techniques to further delay disintegration and absorption in the intestinal tract.

Aqueous suspensions may contain the active ingredient in admixture with pharmacologically acceptable excipients, comprising suspending agents, such as methyl cellulose; and wetting agents, such as lecithin or long-chain fatty alcohols. The said aqueous suspensions may also contain preservatives, coloring agents, flavoring agents and sweetening agents in accordance with industry standards.

Preparations for topical and local application comprise aerosol sprays, lotions, gels and ointments in pharmaceutically appropriate vehicles which may comprise lower aliphatic alcohols, polyglycols such as glycerol, polyethylene glycol, esters of fatty acids, oils and fats, and silicones. The preparations may further comprise antioxidants, such as ascorbic acid or tocopherol, and preservatives, such as p-hydroxybenzoic acid esters.


Parenteral preparations comprise particularly sterile or sterilized products. Injectable compositions may be provided containing the active compound and any of the well known injectable carriers. These may contain salts for regulating the osmotic pressure. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. The pharmaceutical compositions formed by combining the novel compounds of formula I and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.

21


The compounds of the invention are prepared as described below and are screened for receptor-binding efficacy using the neuropeptide-Y receptor binding assay of Example 7.

Synthesis of amidino-urea and diamidino-urea derivatives of the Invention: The invention is also directed to processes for preparing such compounds as well as to pharmaceutical compositions containing them and methods of use.

The compounds of the invention are of two general types each having one of the core structures of the formula below:



Core Structure (a)



Core Structure (b)

Core structure (a) comprises an amidino-substituted urea moiety and core structure (b) comprises a bis-amidino-substituted urea moiety. In each core structure, any of the imino N can optionally be further substituted as shown in the general formula I.

To form the compounds of the invention, derivatives of the core structures are prepared by substitutions $R^{1'}$ and $R^{2'}$ at each terminal amine of the core structures as disclosed below.


General Scheme of Synthesis

The compounds of formulas 1(a) and 1(b) shown above, which are useful in the synthesis of the derivative compounds of the invention, can be synthesized by reacting intermediates 2 and 3 as shown in Schemes I and II:

22


Scheme 1:

Step 1:



Scheme II: Method A

(1) guanidination



Scheme II: Method B



(1) M-acylation

5



(2) guanidination

10

wherein R^{1'} is

15 and wherein W², R⁵, R⁶ and X³ are as previously defined. R^c and R^d are independent and can be lower alkyl or aryl, for example, methyl, ethyl, tert-butyl or phenyl; and M is R⁶ as previously defined.

Scheme I demonstrates the preparation of R^{1'}, R^{2'}-substituted core structures 1(a) and 1(b) by:

- 20 (1) Amidation of blocked intermediate 2 using R^{2'}-NH₂; and
 (2) Deblocking of the imino group of intermediate 4 by hydrolysis of OR^c group thereof, followed by spontaneous decarboxylation.

To produce 1, the substituted (or unsubstituted, blocked) guanidine carbamates 2 are reacted with compounds 3 according to Scheme I. The reactions are performed by stirring or otherwise agitating the components at various temperatures ranging from or about 0°C to from and about 40°C, preferably 10°C to from and about 80°C, preferably in an inert atmosphere, for example, nitrogen or argon, in polar or nonpolar, aprotic, protic or aqueous solvents which include but are not limited to: ethers such as tetrahydrofuran, ethylene glycol methyl ester (glyme), diglyme, dioxane, diethyl ether, dibutyl ether, methyl tert-butyl ether, anisole and the like; esters, exemplified by ethyl acetate or butyl acetate; hydrocarbons, exemplified by hexane, heptane, toluene, xylene and the like; water or mixtures of water and any organic solvents, both water miscible, and water-

25
30

immiscible; dimethylformamide, dimethylacetamide, tetramethylurea; halogenated organic solvents, for example, chloroform, dichloromethane, trichloroethylene, chlorobenzene and dichlorobenzenes; alcohols, for example, methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, phenol, ethylene glycol, and monoethers of ethylene glycol, also known as carbitols.

5 The reaction of 2 with 3 can also be performed neat (without solvent) by stirring or otherwise agitating the components at temperatures ranging from or about 0°C to from and about 140°C, preferably from and about 10°C to and about 80°C. The reactions can be performed in the absence of a catalyst or presence of various catalysts in various amounts ranging from or about 0.01 mol equivalent to 10 mol equivalent, preferentially from and about 0.1 to and about 2 mol
10 equivalent. These include organic bases, for example, triethylamine, diisopropylethylamine and pyridine; or inorganic bases, for example, alkali metal hydrides such as sodium hydride, alkali metal alkoxides such as potassium tert-butoxide, alkali metal fluorides such as cesium or potassium fluoride, alkaline earth hydrides such as calcium hydride; or tetraalkyl ammonium alkoxides such as benzyl trimethylammonium methoxide.

15 The reaction products 4 are freed of the solvent, if necessary, by distillation of the solvent out of the mixture, either at atmospheric pressure or in vacuum. The products are then purified (if necessary) by any of the purification methods known to those skilled in the art, or can be used directly without purification for the next step. The methods useful for the purification include but are not limited to: chromatography on normal phase silica gel, alumina, kieselguhr, Celite, Florisil,
20 microcrystalline cellulose, and similar adsorbents with various solvents used as eluents, either alone or in mixtures; for example, toluene, hexane, ethyl acetate or dichloromethane; or a mixture of solvents such as hexane-ethyl acetate.

 Other chromatographic methods useful for the purification of the product 4 include reverse-phase chromatography on C-18 or analogous solid supports, using solvents such as
25 water-acetonitrile, water-methanol, optionally containing various buffers or other additives, such as trifluoroacetic acid or phosphate buffer. Other methods useful for the purification include extraction of the reaction product and partitioning into various heterogeneous solvent mixtures such as water-ethyl acetate, water-dichloromethane, water-toluene and the like. Other purification methods include recrystallization of crystalline products from various solvents exemplified by ethyl acetate,
30 hexane, isopropyl alcohol and the like; or precipitation (dissolution of the crude product in a solvent the reaction product 4 is soluble in and gradually adding a solvent (precipitant) which precipitates the desired material in purified form (which is then recovered by filtration), or precipitates impurities which are filtered off and the solution is concentrated to obtain the purified 4 material. Examples of solvents used for dissolving the reaction product 4 include ethyl acetate or dichloromethane, an
35 example of the precipitant solvent includes hexane.

The product 4 is usually obtained as a light yellowish foam or a glassy material. The next step consists of removal of the NH blocking groups from the above intermediate 4. When R³ is tert-butoxycarbonyl (t-BOC), the above product is treated with an acidic reagent in a solvent such as water, dioxane, diethyl ether, dichloromethane, toluene, ethyl acetate and the like. The acid reagent can be one of the following: trifluoroacetic acid; hydrogen chloride either as a gas or a solution in a solvent such as water (hydrochloric acid), diethyl ether or dioxane; hydrogen bromide solution in water (hydrobromic acid) or in acetic acid; formic acid; glacial acetic acid and the like. The reaction can be performed at from about -10°C to about 60°C, preferably from about 20°C to about 40°C.


When the reaction is complete, the solvent is removed and the residue may be purified by any of the purification methods outlined above, preferentially reverse phase chromatography, using acetonitrile-water gradient. The product as its trifluoroacetate salt is usually obtained after removal of the solvents in vacuo (e.g. by lyophilization) as a white to off-white amorphous solid. When R³ is benzyl (CBZ), the above product is treated with hydrogen gas at atmospheric pressure or under pressure of from and about 10 to and about 60 psi, or with a hydrogen transfer agent such as 1,4-cyclohexadiene in the presence of a palladium catalyst, either neat, or on various supports, such as charcoal, barium sulfate and the like, the preferred catalyst being commercial 10% palladium on carbon. The hydrogenation can be performed in the presence of various acids, such as hydrochloric acid which provide the corresponding salt counterion. The products are obtained after removal of the solvents in vacuo (e.g. by lyophilization) as a white to off-white amorphous solid. They can be further purified.

The synthesis of these substituted compounds, for example, any of the preferred compounds having the structures of 1(a)-1(n), is carried out in a manner analogous to that for the specific compounds shown in Schemes I and II.


To prepare the compound having a derivatized core structure 1(a) according to Scheme I an amine such as, for example 1,3-(bis-aminomethyl)benzene, is reacted with a guanidinating reagent (di-BOC-amidino-pyrazole) to yield the guanidinated product, for example, (N-(di-BOC-amidino)-1,3-diaminoxylene (3')). The product is then acylated, using for example, 2,3-diphenylpropionyl chloride to yield the acylated guanidinated diamine, for example, N-(di-BOC-amidino)-N'-(2,3-diphenylpropionyl)-1,3-diaminoxylene (5'). The product is again reacted with a diamine, for example 1,3-(bis-aminomethyl)benzene (1), to yield an amidated guanidine derivative.

To prepare a compound having a derivatized core structure 1(b) according to Scheme II, a procedure similar to that described above is followed, with the exception that the guanidinated, M-acylated diamine, for example, N-amidino-N'-(2,3-diphenylpropionyl)-1,3-diaminoxylene (9'), is condensed with an amidinated diamine or its derivative, for example (8'), to yield a derivatized bis-amidino urea (11').


26



(3')




(5')



(9')

5



(11')


10

The condensed product is deblocked to yield the derivatized product having the 1(b) core structure.

27


Preparation of the Intermediates (3) of Scheme I

The R_2 group of Intermediate **3** of Scheme 1 is either R^{2a} or R^{2b} . R^{2a} can be substituted or unsubstituted C_1 to C_{10} branched or straight chain alkyl groups, carbocyclic or heterocyclic 3-12 membered rings, aryl, heteroaryl, arylalkyl, heteroarylalkyl. The substituents on the R^2 moieties may be primary, secondary or tertiary amines, hydroxy, or lower alkoxy groups. Preferred R^{2a} groups are






wherein n , m , and o are 0 to 6, preferably 1-3; v is 0-6, preferably 1-2; R^{20} to R^{23} are any substituent as defined above for R^5 respectively and X is O, S, NH or N-alkyl.

R^{2b} is prepared from R^{2a} by amidination thereof:



The compounds of general formula **3** wherein R^2 is R^{2b} are obtained by reacting the appropriate amine R^{2a} with any of the guanidination agents known to those skilled in the art, for example, 1-amidinopyrazole, S-methylisothiurea sulfate, according to the method and the reagents shown below.




Either of the amine intermediates 3 is then utilized in the next step and reacted with 2 to form the amidated product 4 either in their crude state or are purified by any of the standard purification methods, for example, chromatography, before use in the next step.

5 The reagents necessary to prepare the amidinating reactants are either commercially available (Aldrich, Milwaukee, Wisconsin) or they can be obtained by the methods already described in the organic chemistry literature.

Using $R^{2a}\text{-NH}_2$ as a reactant in the amidation step, one obtains a product having core structure (a) amidino-urea; using $R^{2b}\text{-NH}_2$ as a reactant, wherein R^{2b} comprises an amidino moiety, one obtains a product having core structure (b), diamidino-urea.




Core Structure (a)



Core Structure (b)

Preparation of Intermediates of the General Formula 8

25 Intermediate reactants of general formula 8 (or 2) having the formula

8

are prepared according to Scheme II for use in a manner similar to reactant 2 in the synthesis of Scheme I. Method A of Scheme I comprises a step of guanidinylation of a diamine comprising a Q species followed by M-acylation at the terminal amine thereof. Method B comprises, first, M-acylation of the diamine (or mono-protected diamine by a group such as BOC or CBZ, followed by


29

deprotection), followed by guanidination.

The acylations are performed using method generally known to those skilled in the art and described in the standard works such as Houben-Wyle, Methoden de Organisch Chemie (Methods of Organic Chemistry) Georg-Thieme, Verlag Stuttgart, Germany, namely under conditions which

5


The functionalities are defined as M, wherein M is M¹ or M², wherein M² is M¹-NH- and M¹ is, for example, straight or branched chain alkyl or ester group, aryl, arylalkyl, diarylalkyl, arylalkoxy, arylthio, heteroalkyl, heteroarylalkyl. Preferably, M is one of the following structures



wherein all X's are common ring substituents.

10

Q is preferably



wherein X³ is as defined above; r, s, t and u are 0-10, preferably 2-6; t is 1-10, preferably 2-6, and u

is 0-10, preferably 2-6.


The M-acylations can be performed using standard acylating agents such as acyl halides, (esp. chlorides), imidazolides, anhydrides, isocyanates, and other conventional agents.

The reactions are performed in organic solvents such as chloroform, toluene, dichloromethane, tetrahydrofuran, and similar solvents at temperatures ranging from about -78°C to about 80°C, preferably between about 0°C and 30°C, optionally in the presence of organic tertiary bases such as triethylamine, pyridine, diisopropylethyl amine and similar agents. The acylations can also be performed in aqueous media under usual conditions generally known as Schotten-Baumann procedures using sodium hydroxide as a base and an acid chloride as the acylating agent.

Method A:

According to Scheme II, Method A, guanidination of the Q-species diamine using a di-blocked guanidination reagent bearing a leaving group L is followed by M-acylation at the free terminal amine group. According to Method B, the steps of the method are reversed, and acylation of a Q-species diamine is followed by guanidination at the terminal amine. The guanidination is performed in either method by reacting a reagent having a substituted or unsubstituted transferable amidino group connected to L with an appropriate primary or secondary amine in an organic solvent such as tetrahydrofuran (THF) at temperatures ranging from about 0°C to about 110°C, preferably from about 20°C to about 60°C. Such reagents and reactions have been previously described in the literature.

The guanidination reagents can be, for example,



wherein the leaving group, L, is 1-pyrazolyl or CH₃-S, and the amino N's and imino N's are blocked with t-Boc groups. The reagent is prepared by modifications of the literature procedure (Bernatowitz, M.S. et al. (1992) J. Org. Chem 57:2497).


The reactions are performed in an organic solvent such as THF or aqueous solvent at from about 0°C to about 80°C, optionally in the presence of a base such as sodium hydroxide, triethylamine, pyridine and the like. Amino blocking agents useful in the above methods are disclosed in Bodansky, M. Principles of Peptide Synthesis Springer-Verlag, Berlin (1984).

The following synthesis protocols refer to intermediate compounds and final products identified by number in Schemes I-IV. The preparation of the compounds of the present invention is described in detail using the following examples, but the chemical reactions described are disclosed in terms of their general applicability to the preparation of the NPY ligands of the invention. Occasionally, the reaction may not be applicable as described to each compound included within the disclosed scope of the invention. The compounds for which this occurs will be readily recognized by those skilled in the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, that is, by appropriate protection of interfering groups, by changing to alternative conventional reagents, or by routine modification of reaction conditions. Alternatively, other reactions disclosed herein or otherwise conventional will be applicable to the preparation of the corresponding compounds of the invention. In all preparative methods, all starting materials are known or readily preparable from known starting materials; all temperatures are set forth in degrees Celsius; and, unless otherwise indicated, all parts and percentages are by weight. Positive ESI spectra were recorded on a Finnegan SSQ 7000.

It is believed that one skilled in the art can, using the preceding description, utilize the invention to its fullest extent. The following preferred embodiments are, therefore, to be construed as merely illustrative and not limitative for the remainder of the disclosure in any way whatsoever. The structural description of the compounds is to be preferred over nomenclature.


EXAMPLE 1

The synthesis procedures of Example 1 proceed through the steps of the following Scheme III:



Preparation of N-[3-(1,2-diphenylpropionylamidomethyl-phenylmethyl-amidino)]-N-(3-aminomethyl-phenylmethyl)urea (7')

N-(di-BOC-amidino)-1,3-diaminoxylene (3')



To a solution of 1,3-bis-aminomethylbenzene 1 (30.1g, 221 mmol) in 500 mL of THF was added (N,N'-di-Boc-amidino)-pyrazole 2 (34.3g, 110.5 mmol). The mixture was stirred for 2 hours at room temperature. The solvent was removed in vacuum under 40°C, and the resulting oily residue was purified on a silica gel column (25-50% hexane/ethyl acetate) to give 3' (41.8g, 66%) as a pale yellow oil.


¹H-NMR (CDCl₃, 300 MHz) δ 1.48 (s, 9H), 1.52 (s, 9H), 3.05 (s (broad), 2H), 3.87 (s, 2H), 4.61 (d, J=5.2Hz, 2H), 6.33 (t, J=2.1Hz, 1H) 7.18-7.60(m, 4H), 8.57 (s broad, 1H), 11.5 (s broad, 1H).

MS (ESI) M/Z (relative intensity) 379 (M+1 100%) 337 (22%), 27.9 (10%), 179 (20%).

2,3-Diphenylpropionyl chloride

25g of 2,3-diphenylpropanoic acid was dissolved in 80 mL of SOCl₂ (10 eq.). The reaction mixture was stirred under N₂ overnight at room temperature. Extra SOCl₂ removed by evaporation. 2,3-Diphenylpropionylchloride (28g) was obtained as an oil and used without purification.

N-(di-BOC-Amidino)-N'-(2,3-diphenylpropionyl)-1,3-diaminoxylene (5')



To a precooled solution (0°C) of **3** (27.4g, 72.3 mmol) in 300mL of CHCl₃, Et₃N (7.3g, 72.3 mmol) and 2,3-diphenylpropionylchloride (17.6 g, 72.3 mmol) was added. The mixture was stirred for 1 hour at room temperature. The solution was washed with water and brine and concentrated to dryness. The crude residue was dissolved in minimum amount of EtOAc and 300mL of hexane was added. **5** (30.1g, 71% yield) was collected as a white precipitate.

¹H-NMR (CDCl₃), 300 MHz) δ 1.46 (s, 9H), 1.49 (s, 9H), 2.99 (dd, J=6.1Hz, J=13.1Hz, 1H), 3.59 (dd, J=8.6Hz, J=39 Hz, 1H), 3.60 (dd, J=8.7Hz, J=19.9Hz, 1H), 4.09 (dd, J=5.2, J=15.1, 1H), 4.31 (dd, J=6.2, J=15.0, 1H), 4.42 (d, J=5.1Hz, 2H), 6.11(t, J=5.6Hz, 1H), 6.81 (s, 1H), 6.84(s, 1H), 7.11-7.34(m, 12H), 8.47(t, J=5.0Hz, 1H), 11.55(s, 1H).
MS (ESI) M/Z (relative intensity) 587(M+1, 100%), 545(12%), 487(18%), 387(30%) 345(20%).

A solution of **5'** (2.5g, 4.3mmol) and 1,3-diaminoxylene (590mg, 4.3mmol) in 100mL of THF was heated to reflux for 5 hours. The solvent was evaporated to dryness. Chromatography (CH₂Cl₂/MeOH 95:5) gave 750mg of **6** (28% yield).

¹H-NMR (CDCl₃), 300mHz) δ 1.46(s,9H) 3.0(dd, J=10.3 Hz, J= 17.4 Hz, 1H) 3.47-3.61 (m, 2H), 3.83 (s, 2H), 4.23-4.42 (m, 7H), 5.27(s broad, 1H) 5.52 (s broad, 1H), 6.90 (d, J=6.1 Hz, 1H), 6.96 (s, 1H), 7.10-7.30 (m, 16H), 8.29 (s, 1H), 11.1 (s, 1H)
MS (ESI) M/Z (relative intensity) 649 (M+1, 47%), 366 (100%). 345 (48%).


Deblocking: Compound **6'** (80mg) was dissolved in 3 ml of a mixture of TFA/CH₂Cl₂ (50%). The solution was allowed to stay for 2 hours at room temperature. The solution was evaporated to give 52 mg of **7'**.

¹H-NMR (DMSO, 300MHz) δ 2.95(dd, J=5.5Hz, J=13.5Hz,1H) 3.37 (dd, J=9.8Hz, J=22.2Hz, 1H), 3.88(dd, J=5.7Hz, J=9.5Hz, 1H), 4.03(t, J=5.6Hz, 2H) 4.08(dd J=5.2Hz, J=15.9Hz, 1H) 4.28(dd J=6.1Hz, J=15.8Hz, 1H), 4.33(d, J=5.5Hz, 2H), 4.40(d, J=5.5Hz, 2H), 6.77(d, J=7.0, 2H), 6.98(s, 1H), 7.06-7.41(m, 17Hz), 8.19(m, 2H), 8.28 (s broad, 2H), 8.55(t, d=5.8Hz, 1H), 8.69(s broad, 1H). 9.34(s broad, 1H), 10.80(s broad, 1H). MS (ESI)M/Z (relative intensity) 549 (M+1, 50%), 401 (100%) 359 (84%).






















30

By application of the above methodology, the following compounds can also be prepared:


34



Wherein





35



Wherein
















R =






Wherein

R =










37




Wherein

R =




5

10




Wherein



EXAMPLE 2

The synthesis procedure of Example 2 proceeds through the steps of the following Scheme IV:



N-[3-(1,2-Diphenylpropionylamidomethyl)phenylmethyl-amidino]-N'-[(3-aminomethyl)phenylmethyl-amidino]urea (11')

N-(di-Boc-amidino)-N'-Boc-1,3-diaminoxylene (8')

To a solution of 3' prepared as in Example 1, (1.6 g, 4.2mmol) in 15mL of CH₂Cl₂, di-*t*-butyldicarbonate (1.59 g) was added. The solution was stirred for 20 min at 0°C. The concentrated residue was chromatographed on a silica gel column (hexane/ethyl acetate 5:1) to give 8' (1.9g, 95%).

¹H-NMR (CDCl₃, 300 MHz) δ 1.46(s, 9H), 1.48(s, 9H), 1.52(s, 9H), 4.30(d, J=5.7Hz, 2H), 4.61(d,

40

$J=5.2\text{Hz}$, 2H), 7.20-7.33(m, 4H) 8.55(s broad, 1H), 11.35(s, 1H).

MS(APC1)M/Z (relative intensity) 479 (M+1, 72%), 437(17%), 379(34%), 279(100%) 179(9%).

N-Amidino-N'-(2,3-diphenylpropionyl)-amido-1,3-diaminoxylene (9') A solution of 5', prepared as in Example 1 (5.0g, 8.5mmol) in 25mL of TFA/CH₂Cl₂ (50%) was allowed to stand for 1 hour at room temperature. The reaction mixture was evaporated to dryness. The residue was dissolved in minimum volume of water and 300mL of THF was added. To this solution potassium hydroxide (KOH) was added until it was saturated. The THF layer was collected and concentrated to leave 9' as a pale yellow solid:

Compound 10:

A mixture of 8' (3.29g, 8.5mmol) and 9' (3.29g, 8.5mmol) as shown in the above Scheme IV in 100mL of THF was heated to reflux overnight. The solution was concentrated to dryness. The product (10') was isolated by column chromatography on silica gel (hexane/ethyl acetate 5:1 to 3:1).

¹H-NMR (CDCl₃, 300 MHz) δ 1.45(s, 9H), 1.48(s, 9H), 2.96(dd, $J=6.2\text{Hz}$, $J=13.5\text{Hz}$, 1H), 3.44(dd, $J=8.8\text{Hz}$, $J=13.4\text{Hz}$, 1H), 3.68(m, 1H), 4.1(m, 6H), 4.51(s broad, 2H), 5.0(s broad, 1H), 6.70 (s broad, 3H) 7.07-7.28(m, 18H), 11.06(s, 1H).

¹³C-NMR(CDCl₃, 300MHz) δ 27.9, 28.1, 39.6, 43.1, 44.8, 55.4, 60.2, 79.2, 82.9, 126.0, 126.3, 126.7, 126.8, 127.1, 127.8, 128.1, 128.5, 128.7, 128.8, 128.9, 137.4, 138.1, 138.5, 139.5, 139.6, 139.7, 153.0, 153.1, 154.2, 155.9, 163.4, 172.4.

Deblocking: Compound 10' (3.0g) was dissolved in 20mL of TFA/CH₂Cl₂(50%). the solution was allowed to stand for 1h at room temperature and concentrated by evaporation. 2.6g of crude mixture was obtained, which was purified by preparative HPLC to give (9').

Analytical HPLC was carried out on a column C₁₈ (5 μ , 4.6 x 250 mm); UV-absorbance 0.1 aufs @230; Buffer A, 0.1% TFA; Buffer B, 0.1% TFA in 60% CH₃CN/40%H₂O; flow rate 1.5 ml/min; gradient 0%B to 45'to 100% B. Retention time 35.083 min.


¹H-NMR (DMSO, 300MHz) δ 2.91(dd, $J=5.9\text{Hz}$, $J=13.6\text{Hz}$, 1H), 3.35(dd, $J=9.4\text{Hz}$, $J=13.5\text{Hz}$, 1H), 3.85(s broad, 2H), 3.87(dd, $J=6.0\text{Hz}$, $J=9.2\text{Hz}$, 1H), 4.11(dd, $J=5.4\text{Hz}$, $J=15.3\text{Hz}$, 1H), 4.26 (dd, $J=6.0\text{Hz}$, $J=15.6\text{Hz}$, 1H), 4.32(dd $J=5.7\text{Hz}$, 2H) 4.36(d, $J=6.1\text{Hz}$, 2H), 4.40(d, $J=5.7\text{Hz}$, 1H), 4.51(d, $J=5.8\text{Hz}$, 1H), 6.85(d, $J=7.3\text{Hz}$, 1H), δ 7.13(s, 1H), 7.13-7.40 (m, 16H), 7.98(t, $J=5.9\text{Hz}$, 1H), 8.05(t, $J=5.4\text{Hz}$, 1H), 8.39(t, $J=5.9\text{Hz}$, 1H), 8.60(s broad, 2H) 9.23(d, $J=26.3\text{Hz}$, 1H), 10.40(d, $J=22\text{Hz}$, 1H).

¹³C-NMR (CD₃OD, 300MHz) δ 40.4, 43.6, 44.3, 45.9, 55.8, 127.1, 127.2, 127.3, 127.4, 127.5, 127.6, 128.0, 128.2, 128.9, 129.3, 129.5, 130.1, 130.2, 130.4, 136.4, 136.9, 138.0, 140.4, 140.6, 140.9, 141.4, 155.6, 155.9, 156.0, 158.8, 175.5.

MS(ESI) M/Z (relative intensity) 591 (M+1, 21%) 516(100%), 337(86%).


41

By application of the above methodology, the following compounds were prepared:




Wherein


R =




42



Wherein


















43




Wherein

R =










44




Wherein

R =




5

10



Wherein

Q =




46
EXAMPLE 3

Method A for the preparation of R^2 -NH₂ precursors with general formula 2 (scheme I), according to Scheme II.

5

10



N-(N-BOC-amino-N-BOC-imino)-1,3-bis-aminomethylbenzene

15


To a solution of 30.1g (221 mmol) of 1,3-bis-(aminomethyl)benzene in 500ml of dry tetrahydrofuran was added 34.3g (110.5 mmol) of 1-(N,N-di-BOC-amidino)-pyrazole ((Bernatowitz, M.S. et al. (1992) J. Org. Chem 57:2497). The mixture was stirred for 2 hours at room temperature. The solvent was removed by evaporation in vacuum at under 40°C, and the resulting oily residue was purified by chromatography on a silica gel column, using a gradient of 25 to 50% ethyl acetate in hexane to give after concentration in vacuo 41.8g of the desired material as a yellow oil.

20

By application of the above methodology, the following compounds were also prepared:


25

N-(N-BOC-amino-N-BOC-imino)-1,4-bis-aminomethylbenzene




N-(N-BOC-amino-N-BOC-imino)-1,4-diaminobutane

30




N-(N-BOC-amino-N-BOC-imino)-1,5-diaminopentane

35




N-(N-BOC-amino-N-BOC-imino)-1,5-diaminohexane




47

N-(N-BOC-amino-N-BOC-imino)-trans-1,3-bis-amino methyl cyclohexane




5

N-(N-BOC-amino-N-BOC-imino)-cis-1,3-bis-aminomethyl cyclohexane




10

N-(N-BOC-amino-N-BOC-imino)-2,4-bis-aminomethylthiophene




15

N-(N-BOC-amino-N-BOC-imino)-2,5-bis-aminomethylthiophene




20

N-(N-BOC-amino-N-BOC-imino)-2,4-bis-aminomethylfuran




25

N-(N-BOC-amino-N-BOC-imino)-2,5-bis-aminomethylfuran




30

Example 4



Synthetic Scheme:



Synthesis of Compound 18

5 Same procedure as described for the synthesis of compound 3.

Synthesis of Compound 19

10 Same procedure as described for the synthesis of compound 5.

Synthesis of Compound 20


15 Same procedure as described for the synthesis of compound 6, except tetrahydrofurfurylamine was used.

Synthesis of Compound 21

20 Same procedure as described for the synthesis of compound 7.

¹H NMR (DMSO-D₆) δ 1.48 (m, 1H), 1.82 (m, 3H), 2.9 (dd, 1H), 3.14 (m, 3H), 3.50 (m, 1H), 3.61 (m, 2H), 3.74 (m, 1H), 4.00 (m, 1H), 4.45 (m, 1H), 6.94 (m, 1H), 7.22 (m, 9H), 7.33 (m, 3H), 7.5 (s, 1H), 7.80 (brd s, 1H), 8.60 (brd s, 2H), 9.34 (brd s, 1H), 10.23 (brd, 2H).


By application of the above methodology the following compounds are prepared.




30


¹H NMR (DMSO-D₆) δ 2.96 (dd, 1H), 3.41 (t, 2H), 3.97 (m, 2H), 4.10 (m, 1H), 4.31 (d, 2H), 4.46 (s, 1H), 6.97 (d, 1H), 7.1-7.5 (m, 16H), 7.55 (s, 1H), 8.41 (brd, 3H), 8.67 (brd, 2H), 9.37 (brd, 1H), 10.31 (s, 1H), 10.73 (brd, 1H). MS(APCI): 534.4 (M+1).

35



Example 5⁵⁰

Synthetic Scheme:



Synthesis of Compound 22'

To a solution of diphenylpropanoic acid (3.0g, 13.3 mmol) in 20 mL of CH₂Cl₂ was added 2.7g (13.3 mmol) of 1,3-dicyclohexylcarbodiimide (DCC). After being stirred for 5 minutes, 1.6g (13.3 mmol) of 3-aminobenzylamine was added. The solution was stirred at room temperature for 2 hours. The dicyclohexylurea was removed by filtration. The filtrate was concentrated. The residue was chromatographed on silica gel, eluting with 3:1 hexane:ethyl acetate, to afford 1.9g of N-(1,2-diphenylcarbonyl)-3-aminobenzylamide.

¹H NMR (CDCl₃) δ 2.98 (dd, 1H), 3.66 (m, 2H), 4.08 (m, 1H), 4.31 (dd, 1H), 5.90 (t, 1H), 6.12 (s, 1H), 6.33 (d, 1H), 6.48 (d, 1H), 6.96 (t, 1H), 7.09-7.34 (m, 10H). MS (APCI): 331 (M+1)

Synthesis of Compound 23'

A solution of 190mg (0.61 mmol) of N,N'-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carbox-amidine and 200mg (0.61 mmol) of compound 22 in toluene was heated at reflux for 5 hours. The concentrated residue was chromatographed on silica gel, eluting with 1:4 hexane: ethyl acetate to afford 67mg of 3-[N,N'-bis(tert-butoxycarbonyl)carboxamidino]-N''-(2,3-diphenylpropanoyl)benzyl amide.

Synthesis of Compound 24'


Same procedure as described for the synthesis of compound 6, except tetrahydrofurfuryl amine was used.

¹H NMR (CDCl₃) δ 1.52-1.85 (m, 4H), 1.96 (s, 9H), 2.92 (dd, 1H), 3.10 (m, 1H), 3.4 (m, 1H), 3.51-3.73 (m, 4H), 3.82 (dd, 1H), 3.90 (dd, 1H), 5.90 (s, 1H), 6.25 (s, 1H), 6.62 (d, 1H), 7.10-7.35 (m, 13H), 7.42 (d, 1H), 10.05 (s, 1H).


Synthesis of Compound 25'

Same procedure as described for the synthesis of compound 7.

¹H NMR (DMSO-D₆) δ 1.52 (m, 1H), 1.84 (m, 3H), 2.90 (dd, 1H), 3.16 (m, 1H), 3.30 (m, 2H), 3.64 (qt, 1H), 3.76 (qt, 1H), 3.90 (m, 2H), 4.10 (dd, 1H), 4.31 (dd, 1H), 6.81 (s, 1H), 6.87 (d, 1H), 7.10-7.30 (m, 10H), 7.42 (d, 2H), 7.99 (t, 1H), 8.42 (brd, 1H), 8.61 (t, 1H), 8.97 (brd, 1H), 10.14 (brd, 1H), 10.79 (brd, 1H). MS (ESI): 499.47 (M+1).

Example 6⁵²

Synthetic Scheme:



27

Synthesis of Compound 26

Same procedure as described for the synthesis of compound 22.

5

Synthesis of Compound 27

A solution of 1.0g (3.0 mmol) of N-(1,2-diphenylpropanoyl)-1,3-diaminoxylene and 1.1g (3.0 mmol) of N-(di-boc-amidino)-1,3-diaminoxylene in 20 mL of THF was heated at reflux for 15 hours. The solution was concentrated. To the residue was added 5 mL of 50% TFA in CH₂Cl₂. The solution was stirred at room temperature for 1 hour. The solution was concentrated to afford 380mg of N-[3(1,2-diphenylpropanoylamidomethyl-phenylmethyl)]-N'(3-aminomethyl-phenylmethyl-amidino)urea.

15

¹H NMR (DMSO-d₆) δ 2.92 (dd, 1H), 3.36 (dd, 1H), 3.86 (d, 2H), 3.95 (d, 2H), 4.08 (dd, 1H), 4.29 (dd, 1H), 5.08 (brd, 4H), 6.84 (d, 1H), 7.10 (s, 1H), 7.20 (m, 6H), 7.32 (m, 3H), 7.43 (m, 3H), 8.56 (m, 4H).

20

Synthesis of Compound 28

A solution of 20.0g (86 mmol) of meso-2,3-diphenylsuccinonitrile in 350 mL (345 mmol) of BH₃-THF (1.0M in THF) was heated at reflux for 18 hours. The solution was cooled to 0°C. To this solution was added dropwise 100 mL of 3N HCl and stirred for 20 minutes. The solution was reflux for 2 hours and stirred at room temperature for 3 hours. The resulting white precipitate, (19.0g) was collected by filtration and dried.

30

¹H NMR (DMSO-d₆) δ 2.7 (brd, 2H), 2.8 (m_{brd}, 4H), 7.5 (m, 10H), 7.9 (brd, 4H). MS(APCI): 240 (M+1).

35

Synthesis of Compound 29

Same procedure as described for the synthesis of compound 3.

40

¹H NMR (CDCl₃) δ 1.3 (s, 18H), 1.4 (s, 18H), 3.2 (m, 2H), 3.3 (m, 2H), 3.5 (m, 2H), 7.2 (m, 2H), 7.3 (m, 8H), 7.9, (t, 2H). MS(APCI): 724 (M+1).

Synthesis of Compound 30

45

Same procedure as described for the synthesis of compound 6, except 5-hydroxypentylamine was used.

¹H NMR (CDCl₃) δ 1.40 (s, 9H), 1.45 (s, 9H), 1.50 (s, 9H), 1.60 (m, 6H), 3.15 (m, 5H), 3.35 (m, 1H), 3.50 (m, 2H), 3.65 (t, 2H), 4.95 (t, 1H), 7.3 (m, 10H), 7.65 (t, 1H), 7.90 (t, 1H).



Synthesis of Compound 31

5 Same procedure as described for the synthesis of compound 7.




^1H NMR (DMSO-d_6) δ 1.1 (m, 2H), 1.2 (m, 4H), 2.8 (brd, 4H), 3.2 (m, 4 H), 3.8 (brd, 6H), 7.2 (m, 10H), 7.3 (s, 1H), 7.4 (s, 1H), 8.2 (brd, 2H), 8.7 (brd, 1H), 10.0 (brd, 1H).

10



By use of the methodology shown in Examples 1-6, the following compounds are prepared:





15







20







55



5







10





15




56



5







10







15

57







5







10

58







5







10



59





5





10





60





5






10







15



61







5







10



62




5



10





EXAMPLE 7





Radioligand Binding Assay

The activity of the compounds at NPY receptors was assessed by determining their ability to inhibit the binding of ^{125}I -labeled Peptide YY (^{125}I -PYY) to NPY receptors in membranes derived from clonal cell lines. PYY was radioiodinated using Chloramine T and the product was purified by reverse phase HPLC. The source of the membranes was the human neuroblastoma cell line SK-N-MC. Briefly, SK-N-MC cells were harvested with an EDTA-containing saline solution, resuspended in a hypotonic buffer and homogenized with a Polytron tissue disrupter, the homogenate was centrifuged at 1000x g for 10 minutes at 4°C. The resulting supernatant was centrifuged at 48000xg for 20 min at 4°C. The membranes were washed by centrifugation and resuspension, and the final pellet stored at -70° until use. The binding of ^{125}I -PYY (30-50 pM) \pm test

64

compounds to thawed membranes was performed in a buffer consisting of 25 mM HEPES pH 7.4, 2 mM MgCl₂, 2.5 mM CaCl₂, 5mM KCl, 135mM NaCl, and 0.1% bovine serum albumin (BSA) and 100 µg/ml bacitracin. The assays were incubated for 90 min at 37°, and were terminated by rapid filtration over glass fiber filters that had been pre-soaked with 0.1% polyethylenimine. ¹²⁵I-PYY binding was quantitated with either a Packard TopCount scintillation or Packard Cobra gamma counter. Dose-response data were analyzed by non-linear regression using the computer program Prism (GraphPad Software, San Diego, CA). IC₅₀ values representing the concentration of drug that produced a 50% displacement of the binding of ¹²⁵I-PYY are given.


Biological Activity

IC₅₀ = 70 nMIC₅₀ = 100 nMIC₅₀ = 85 nMIC₅₀ = 500 nM

65

CLAIMS:

1. A compound of the formula



wherein


A is O, S or N-R, wherein R is lower alkyl (C₁-C₈);

D is O, S or N-R⁷;

W is N, CH or C-R⁸;

R¹ and R³ are independently H, straight or branched, cyclic or acyclic, saturated or unsaturated C₁-C₁₄ alkyl radicals, optionally substituted by hydroxy, lower alkoxy, alkylthio, aryloxy or arylthio groups, wherein said aryl-bearing groups are optionally substituted by halogen, lower alkoxy, alkylthio, lower alkyl, trifluoromethoxy, trifluoroethoxy or trifluoromethyl groups, and optionally said alkyl groups are substituted by cyclic structures selected from the group consisting of rings having a ring size of from 3 to 10 atoms, or said alkyl groups are substituted by aromatic or heteroaromatic moieties, said aryl or heteroaryl groups optionally containing substituents on the aryl ring selected from the group consisting of lower alkyl, alkoxy, amino, lower alkylamino, lower acylamino, halogens, and trifluoromethyl or trifluoromethoxy groups;

R² is




Wherein

W₂ is C=O, SO₂, C(O)NH; SO; or is absent;

Q is


(a) a substituted or unsubstituted (-CH₂)_z, wherein z = 1 to 12, and when -CH₂- is substituted, the substituting groups are lower alkyl, aryl or heteroaryl; and when z>1, at least one -CH₂- group is optionally replaced by a heteroatom selected from the group consisting of O, S, or a substituted or unsubstituted N, wherein the substituting moiety is selected from the group consisting of lower alkyl, aryl, heteroarylalkyl and hydrogen;

(b) a saturated carbocyclic or heterocyclic ring of the formula $(-CH_2-)_x$



wherein l and m are 0-5, and wherein $x = 3-12$, preferably 3-8, and optionally, one or more $-CH_2-$ groups are substituted by a radical selected from the group consisting of saturated or unsaturated lower alkyl, cycloalkyl, aryl and heteroaryl; and optionally at least one of the $-CH_2-$ groups is replaced by a heteroatom selected from the group consisting of O, S, Se and substituted or unsubstituted N, and when N is substituted, the substituting group is selected from the group consisting of lower alkyl, aryl, heteroaryl and hydrogen;


(c) a carbocyclic or heterocyclic aromatic ring of the formula $(-CH=CH-)_y$;



wherein l and m are 0-5, and wherein $y \geq 2$ and optionally at least one of the $-CH-$ groups is substituted by X^1 , X^2 or both X^1 and X^2 wherein X is any ring substituent, for example saturated or unsaturated, linear or branched alkyl groups, lower alkoxy groups or halogens, and optionally, at least one of the $-CH-$ groups is replaced by N, or alternatively, one of the $-CH=CH-$ groups is replaced by a heteroatom selected from the group consisting of O, S, Se and $N-R^{11}$; also optionally, at least one of the $-CH=CH-$ groups is a junction to which another ring structure, either saturated or unsaturated can be fused, thus forming condensed aromatic or heteroaromatic systems selected, for example, from the group consisting of naphthalene, indole, benzofuran, quinoline, quinazoline and benzodioxane classes;

X^3 is a substituent on Q which can be H, lower alkyl, aryl, lower alkoxy, hydroxy, trifluoromethyl, and similar common ring substituents.

R^4 is selected from the group consisting of the following general formulas:



wherein A^1 is O, S, NH or N-lower alkyl or aryl;

R^5 to R^9 , R^{11} and R^{12} are independently selected from the group consisting of H, linear or branched, saturated or unsaturated, cyclic or acyclic, substituted or unsubstituted C_1 to C_{14} alkyl radicals, or aryl or heteroaryl radicals, and when any one of R^5 to R^9 , R^{11} or R^{12} is a

substituted aryl or heteroaryl radical, the substituting group is selected from members of the group consisting of halogen, lower alkoxy, alkylthio, lower alkyl, trifluoromethoxy and trifluoromethyl, and when any one of R^5 to R^9 , R^{11} or R^{12} is a substituted alkyl radical, the substituting moiety is selected from the group consisting of non-aromatic cyclic systems having from 3 to 14 ring atoms, and aromatic and heteroaromatic systems and heterocyclic rings having from 4-12 ring members, and said aromatic and heteroaromatic rings optionally are substituted by radicals selected from the group consisting of lower alkyl, alkoxy, amino, lower alkylamino, lower acylamido, halogens, perfluoroalkyl, and perfluoro-lower alkoxy; or

10

R^6 is H, C_1 to C_{14} alkyl, straight or branched, cyclic or acyclic, saturated or unsaturated; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; condensed aryl-lower alkyl; condensed heteroaryl-lower alkyl; diaryl-lower alkyl; bis-heteroaryl-lower alkyl; or heteroaryl-lower alkyl-aryl; or partially or fully saturated derivatives thereof; or R^6 can be R^6 which is R^6 -NH or R^6 -N-lower alkyl;

15


R^{10} is hydrogen, C_1 - C_{12} alkyl, straight or branched, saturated or unsaturated, cyclic or acyclic groups, optionally containing double or triple bonds; aryl, optionally substituted with groups such as halogen, lower alkyl, alkoxy, aminoalkyl, di-(lower alkyl)-amino-lower alkyl, hydroxy; arylalkyl; aryloxyalkyl; 2-tetrahydrofurfuryl; 3-tetrahydrofurfuryl; terminal hydroxyalkyl with C_2 - C_{10} hydrocarbon chains and amidoalkyl such as 2-acetamidoethyl; or R^9 and R^{10} can optionally form a 3 to 10-membered ring; and

20

the compounds comprise any optically active isomers thereof in the form of separated, pure or partially purified optical isomers or racemic mixtures thereof, and pharmaceutically acceptable salts thereof.

25

2. A compound having the structure of



30

wherein R^1 , R^3 , R^5 , R^7 , R^9 , R^{10} and X^3 are as defined in Claim 1 and

35


68

Q is selected from the group consisting of

$$Q =$$


3. A compound according to Claim 2 wherein R6 is selected from the group consisting of


R =



20


69

3. A compound according to Claim 2 wherein R⁶ is selected from the group consisting of



5

5. A compound according to Claim 2 wherein R⁹ is selected from the group consisting of




10


15

70

6. A compound according to Claim 2 wherein R^9 is selected from the group consisting of




- 25 7. A compound having the structure



SUBSTITUTE SHEET (RULE 26)


8. A compound having the structure

5




9. A compound having the structure

10



10. A compound having the structure

15



- 20 11. A pharmaceutical composition comprising any one of the compounds according to Claims 1-10 in a pharmaceutically acceptable carrier.

12. The use of any one of the compounds of Claims 1-10 in the preparation of a medicament.

25

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/14854

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN (CAS-ON-LINE)DATABASES:file Registry, File Caplus, File Marpat,File CAS-React (1907-1997), File Beilstein (1779-1995).

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,482,947 A (TALLEY et al.) 09 January 1996, see columns 1-52.	1-12
X,P	US 5,583,238 A (J. S. NG et al.) 10 December 1996, see entire document.	1-12

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

08 OCTOBER 1997

Date of mailing of the international search report

02 DEC 1997

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ALAN L. ROTMAN

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/14854

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 31/34, 31/35, 31/415, 31/44, 31/445, 31/505, 31/47; C07C 275/26, 275/28; C07D 211/08, 213/56, 213/58, 215/12, 233/61, 235/14, 239/32, 265/30, 307/22, 309/14

A. CLASSIFICATION OF SUBJECT MATTER:

US CL : 514/237.8, 256, 311, 357, 400, 459, 461, 482, 588, 596, 634, 635; 544/164, 332; 546/176, 192, 331, 332, 337; 548/304.4, 336.5, 338.1, 566; 549/426, 493.

B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

514/237.8, 256, 311, 357, 400, 459, 461, 482, 588, 596, 634, 635; 544/164, 332; 546/176, 192, 331, 332, 337; 548/304.4, 336.5, 338.1, 566; 549/426, 493.

THIS PAGE BLANK (USPTO)